Health Trials

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

ConditionsNSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLCNSCLC (Non-small Cell Lung Carcinoma)NSCLC (Advanced Non-small Cell Lung Cancer)
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorRevolution Medicines, Inc.

About this trial

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

Eligibility criteria

Qualifiers

At least 18 years old and has provided informed consent.

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Pathologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy.

Measurable disease per RECIST v1.1.

Disqualifiers

Prior therapy with direct RAS-targeted therapy or docetaxel.

Untreated central nervous system (CNS) metastases.

Medically significant comorbidities (significant cardiovascular disease, lung disease, or impaired GI function).

Ongoing anticancer therapy.

Trial design

Treatments tested in this trial

  • daraxonrasib
  • docetaxel

Treatment groups

590 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Revolution Medicines, Inc.

Lead sponsor

Source ClinicalTrials.gov